ID   KAS-6/1
AC   CVCL_9544
SY   KAS 6/1; KAS6/1; KAS-6; KAS61
DR   Wikidata; Q54899506
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1182/blood.V112.11.2732.2732;
RX   PubMed=8656685;
RX   PubMed=10936422;
RX   PubMed=18647998;
RX   PubMed=24013424;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Characteristics: Produces IgG kappa.
CC   Characteristics: IL6 dependent.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M524 ! KAS-6/2
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-09-24; Version: 16
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017); University of Toronto; Toronto; Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   DOI=10.1182/blood.V112.11.2732.2732;
RA   Keats J.J., Arendt B.K., Braggio E., Barrett M.T., Price-Troska T.L.,
RA   Fonseca R., Bergsagel P.L., Jelinek D.F.;
RT   "Comparison of multiple myeloma donor patient samples and derived cell
RT   lines identifies a confirmed hyperdiploid myeloma cell line and
RT   demonstrates remarkable genetic similarity between cell lines and
RT   patient samples.";
RL   Blood 112 Suppl. 1:2732a-2732a(2008).
//
RX   PubMed=8656685;
RA   Westendorf J.J., Ahmann G.J., Greipp P.R., Witzig T.E., Lust J.A.,
RA   Jelinek D.F.;
RT   "Establishment and characterization of three myeloma cell lines that
RT   demonstrate variable cytokine responses and abilities to produce
RT   autocrine interleukin-6.";
RL   Leukemia 10:866-876(1996).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=24013424; DOI=10.4161/cc.26193; PMCID=PMC3865013;
RA   Walters D.K., Arendt B.K., Jelinek D.F.;
RT   "CD147 regulates the expression of MCT1 and lactate export in multiple
RT   myeloma cells.";
RL   Cell Cycle 12:3175-3183(2013).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//